Danisco to Acquire Genencor
27 Enero 2005 - 7:16AM
PR Newswire (US)
Danisco to Acquire Genencor COPENHAGEN, Denmark and PALO ALTO,
Calif., Jan. 27 /PRNewswire-FirstCall/ -- Danisco A/S (Copenhagen
Stock Exchange) ("Danisco"), one of the world's largest producers
of food ingredients, and Genencor International, Inc. (NASDAQ:GCOR)
("Genencor"), a diversified biotechnology company that develops and
delivers innovative products and services into the health care,
agri-processing, industrial and consumer markets, today jointly
announced that they have signed a definitive agreement for Danisco
to acquire all of the outstanding shares of common stock of
Genencor, other than those held by Danisco, Eastman Chemical
Company ("Eastman") or their respective subsidiaries, for $19.25
per share in cash. In connection with the definitive agreement with
Genencor, Danisco has entered into a definitive stock purchase
agreement with Eastman under which Danisco will acquire all of the
outstanding shares of common stock of Genencor held by Eastman for
$15 per share in cash and all of the outstanding shares of
preferred stock of Genencor held by Eastman for $44 million in
cash. Danisco and Eastman currently each own approximately 42% of
Genencor's outstanding shares of common stock and 50% of Genencor's
outstanding shares of preferred stock. "Being an advanced and
recognised biotechnology company, Genencor will expand Danisco's
knowledge base significantly and broaden our access to an important
new business area, industrial enzymes," said Alf Duch-Pedersen,
Chief Executive Officer of Danisco. "Our two companies know each
other well and the synergy is obvious," said JJ Bienaime, Chairman
and Chief Executive Officer of Genencor. "Together, we will have
the depth and the reach to achieve the vision we've had for our
business." The acquisition of the shares of Genencor's common stock
for $19.25 per share will be effected by means of a cash tender
offer for all of the outstanding shares of common stock of
Genencor, other than those held by Danisco and its subsidiaries,
followed by a merger in which all Genencor stockholders, other than
Danisco and its subsidiaries, who have not tendered their shares
will receive the same per share price. The acquisition agreement is
subject to certain conditions, including the tender of a majority
of the outstanding shares of common stock of Genencor other than
those held by Danisco, Eastman, the officers and directors of
Genencor and its subsidiaries and the respective affiliates of each
of the foregoing, receipt of regulatory approvals and other
conditions. Subject to those conditions, Danisco and Genencor
currently expect the acquisition to be completed by May 31, 2005. A
special committee comprised of independent directors of Genencor
has reviewed the transaction on behalf of the Genencor stockholders
unaffiliated with Danisco and Eastman. Upon the recommendation of
the special committee, the board of directors of Genencor has
approved the acquisition agreement and the transaction. About
Danisco Danisco develops and produces food ingredients, sweeteners
and sugar. The group employs around 9,000 people in some 40
countries and reported net sales of DKK 16.4 billion (USD 2.9
billion) in 2003/04. Danisco's broad product portfolio includes
emulsifiers, stabilisers, cultures, flavours and sweeteners such as
xylitol and fructose. The majority of these ingredients are
produced from natural raw materials and contribute, for instance,
to improving the texture in bread, ice cream, yoghurt and other
products. Danisco is also one of the largest and most efficient
sugar producers in Europe. About Genencor Genencor International is
a diversified biotechnology company that develops and delivers
innovative products and services into the health care,
agri-processing, industrial and consumer markets. Using an
integrated set of technology platforms, Genencor's products deliver
innovative and sustainable solutions to improve the quality of
life. Genencor traces its history to 1982 and has grown to become a
leading biotechnology company. Genencor has principal offices in
Palo Alto, California; Rochester, New York; and Leiden, The
Netherlands. Notice to Read Tender Offer Materials The description
contained herein is neither an offer to purchase nor a solicitation
of an offer to sell shares of Genencor. At the time the tender
offer is commenced, an indirect wholly-owned subsidiary of Danisco
("Danisco's acquisition subsidiary") and Danisco intend to file a
Tender Offer Statement on Schedule TO with the Securities and
Exchange Commission containing an offer to purchase, forms of
letters of transmittal and other documents relating to the
transaction and Genencor intends to file a
Solicitation/Recommendation Statement on Schedule 14D-9 relating to
the transaction with the Securities and Exchange Commission.
Danisco's acquisition subsidiary, Danisco and Genencor intend to
mail these documents to the stockholders of Genencor. Genencor and
Danisco also intend to file a Transaction Statement on Schedule
13E-3 with the Securities and Exchange Commission relating to the
transaction. These documents will contain important information
about the transaction and stockholders of Genencor are urged read
them carefully when they become available. Stockholders of Genencor
will be able to obtain a free copy of these documents (when they
become available) at the website maintained by the Securities and
Exchange Commission at http://www.sec.gov/. In addition,
stockholders will be able to obtain a free copy of these documents
(when they become available) from Danisco by contacting Danisco at:
Langebrogade 1, P.O. Box 17, DK-1001 Copenhagen K, Denmark,
attention: Investor Relations, or from Genencor by contacting
Genencor at: 925 Page Mill Road, Palo Alto, CA 94304, attention:
Investor Relations. DATASOURCE: Danisco A/S; Genencor
International, Inc. CONTACT: For Genencor - Investor Relations, Tom
Rathjen, +1-650-846-7500, or Media Relations, Jack Huttner,
+1-585-256-5200; or For Danisco - Investor Relations, Michael von
Bulow: +45-3266-2912, or Media Relations, Nathalie Weber,
+45-3266-2913 Web site: http://www.danisco.com/
http://www.genencor.com/
Copyright
Genencor International (NASDAQ:GCOR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Genencor International (NASDAQ:GCOR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025